Vifor International AG (CSL Vifor): Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus

Recommendation will enable eligible patients in England, Wales and Northern Ireland to access the first licensed treatment for moderate-to-severe chronic kidney disease (CKD)-associated pruritus

Related Keywords

Melbourne ,Victoria ,Australia ,United States ,Northern Ireland ,Craigavon ,United Kingdom ,Switzerland ,American ,Takeshi Hasegawa ,Philippa Csomor ,Ronaldl Pisoni ,Warren Wen ,Pablo Antonio Urena Torres ,Gewinn Nur ,Fitsum Guebre Egziabher ,Issa Al Salmi ,Kieran Mccafferty ,Hughc Rayner ,Christopher Posner ,Angelo Karaboyas ,Prnewswire Vifor Fresenius ,Thilo Schaufler ,Nidhi Sukul ,Saeed Mg Al Ghamdi ,Fabio Dorigotti ,International Comparisons Of Prevalence ,Cara Therapeutics Inc ,Nasdaq ,England National Institute For Health ,Linkedin ,Twitter ,National Health Service ,Head Global Medical Affairs ,Company Kapruvia ,Barts Health ,Instagram ,Fresenius Medical Care ,Regulatory Agency ,National Registry Study ,American Society Of Nephrology ,Fresenius Medical Care Renal Pharma ,Cara Therapeutics ,National Institute ,Care Excellence ,Chief Executive Officer ,Consultant Nephrologist ,New England Journal ,Vifor Fresenius Medical Care Renal Pharma ,Registry Study ,International Comparisons ,American Society ,Self Reported Pruritus ,Patient Reported Outcomes ,Kidney Medicine ,Uremic Pruritus ,Vifor ,Nternational ,Apruvia ,Difelikefalin ,Ecommended ,England ,Ice ,Treatment ,Adults ,Moderate ,Evere ,Ssociated ,Pruritus ,